Author: William Mack

AKBA – Akebia Therapeutics: Buy This Undervalued Stock At Just 77% Of Revenue

Anterior or front xray view of the kidneys and the ureter 3D rendering illustration with male body contours. Human anatomy, medical, biology, science, healthcare concepts.

libre de droit

In agreement with Seeking Alpha Quant, I rate Akebia Therapeutics, Inc. (NASDAQ:AKBA) a Strong Buy on the basis of its overly discounted revenue, which has strong prospects in a very large Chronic Kidney Disease, or CDK, Total Addressable Market, or TAM. AKBA is

TIO – Tingo Group: Buy The Dip

Nigeria money, Naira paper banknotes, Creative business and finance concept

Andrzej Rostek/iStock via Getty Images

Tingo Group (NASDAQ:TIO) may be the best investment opportunity available to retail investors for some time to come. Seeking Alpha Quant has ranked it #1. When taking into consideration Tingo’s balance sheet and cash

Tingo Revenue Guidance

Tingo Revenue Guidance (Tingo Group)